Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

Sanofi and Regeneron Pharmaceuticals said their jointly developed Dupixent anti-inflammatory blockbuster drug achieved primary and secondary goals in a late-stage study for allergic fungal ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...